Status:

COMPLETED

A Phase 3, International, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy and Safety Trial of Linaclotide Administered Orally for 12 Weeks to Patients With Irritable Bowel Syndrome With Constipation (IBS-C)

Lead Sponsor:

AstraZeneca

Collaborating Sponsors:

Ironwood Pharmaceuticals, Inc.

Conditions:

Irritable Bowel Syndrome With Constipation (IBS-C)

Eligibility:

All Genders

18+ years

Phase:

PHASE3

Brief Summary

This clinical trial is an international, multicenter, randomized, double-blind, placebo-controlled, parallel-group trial comparing one dose of linaclotide to placebo. Approximately 800 patients with a...

Eligibility Criteria

Inclusion

  • Patient has signed an Informed Consent Form(ICF).
  • Patient Must not be pregnant or breastfeeding and agree to use birth control
  • Patient meets the colonoscopy requirements defined by the American Gastroenterological Association guidelines and no clinically-significant laboratory or physical examination findings;
  • Patient meets protocol-defined criteria for Irritable Bowel Syndrome with Constipation(IBS-C), including stool frequency, straining, stool consistency, abdominal pain, and abdominal discomfort criteria
  • Patient meets protocol-defined eDiary completion Compliance and agrees to refrain from making any new, major life-style changes that may affect IBS-C symptoms

Exclusion

  • Recent history of mushy or watery stools
  • Various medical conditions, medical histories, or family medical histories that would not make the patient a good candidate for the study
  • Patient currently has both unexplained and clinically significant alarm symptoms or systemic signs of infection or colitis.
  • Surgery to the gastrointestinal tract
  • Usage of prohibited medications

Key Trial Info

Start Date :

July 1 2013

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

May 1 2015

Estimated Enrollment :

1722 Patients enrolled

Trial Details

Trial ID

NCT01880424

Start Date

July 1 2013

End Date

May 1 2015

Last Update

September 27 2016

Active Locations (82)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 21 (82 locations)

1

Research Site

Huntsville, Alabama, United States

2

Research Site

North Little Rock, Arkansas, United States

3

Research Site

Phoenix, Arkansas, United States

4

Research Site

Artesia, California, United States

A Phase 3, International, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy and Safety Trial of Linaclotide Administered Orally for 12 Weeks to Patients With Irritable Bowel Syndrome With Constipation (IBS-C) | DecenTrialz